Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3885026 A
Publication typeGrant
Publication dateMay 20, 1975
Filing dateSep 10, 1973
Priority dateSep 20, 1972
Also published asDE2246013A1
Publication numberUS 3885026 A, US 3885026A, US-A-3885026, US3885026 A, US3885026A
InventorsHelmut Heinemann, Werner Rothe
Original AssigneeBoehringer Mannheim Gmbh
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Preparation of porous tablets
US 3885026 A
Abstract
In the production of tablets which are to undergo disintegration in use wherein the tablet components are mixed and pressed into predetermined shape, the improvement which comprises incorporating into the mix at least one inert readily volatilizable solid adjuvant, pressing the mix into shape, and thereafter volatilizing the adjuvant, whereby the resulting tablets are porous, strong, shape retaining and readily disintegratable. Volatilization can be effected by sublimation or application of vacuum. The adjuvant preferably comprises urethane, urea, ammonium carbonate, ammonium bicarbonate, hexamethylene-tetramine, benzoic acid, phthalic anhydride, naphthalene or camphor present in about 5 to 50 percent, especially about 10 to 30 percent, by weight of the total tablet mix.
Images(5)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent [191 Heinemann et al.

[451 May 20, 1975 PREPARATION OF POROUS TABLETS [75] Inventors: I-Ielmut Heinemann, Heidelberg;

Werner Rothe, Hockenheim, both of Germany [73] Assignee: Boehringer Mannheim GmbH, Mannheim-Waldhof, Germany [22] Filed: Sept. 10, 1973 [21] Appl. No.: 395,796

[30] Foreign Application Priority Data [58] Field of Search 264/49, 54, 117, 140, 101, 264/109, 122; 23/293 R, 293 A; 241/1, 2, 18, 30; 424/14; 239/60; 252/135, 531

[56] References Cited UNITED STATES PATENTS 1,742,515 1/1930 Mandell 264/49 X 2,887,437 5/1959 Klioze et a1 424/14 3,175,521 3/1965 l-lershberg 424/14 X 3,371,984 3/1968 Kelly et a1 239/60 X 3,424,842 1/1969 Numberg 264/117 X 3,632,778 1/1972 Sheth et a1 264/117 X 3,639,286 2/1972 Ballestra et a1. 252/135 X 3,649,545 3/1972 Susuki et a1. 252/135 X 3,653,914 4/1972 Schmitt 264/122 X 3,674,700 7/1972 Gaiser 252/135 3,719,599 3/1973 Crivellaro et a1. 424/14 X 3,739,048 6/1973 Morita 264/54 X 3,781,428 12/1973 l-lennart et a1 239/60 X 3,789,119 1/1974 Fusari 264/117 X R18,506 6/1932 Mandel 264/49 X FOREIGN PATENTS OR APPLICATIONS 83,244 12/1971 Germany 264/49 OTHER PUBLICATIONS The Condensed Chemical Dictionary, Seventh Edition, Completely revised and enlarged by Arthur and Elizabeth Rose, New York, Reinhold, C1966, page 995.

Handbook of Chemistry and Physics, 52nd Edition, Editor: Robert C. Weast, Cleveland, Ohio, The Chemical Rubber Co., 01971, Page C-232.

Primary Examiner-Philip E. Anderson Attorney, Agent, or Firm-Burgess & Dinklage & Sprung [5 7] ABSTRACT In the production of tablets which are to undergo disintegration in use wherein the tablet components are mixed and pressed into predetermined shape, the improvement which comprises incorporating into the mix at least one inert readily volatilizable solid adjuvant, pressing the mix into shape, and thereafter volatilizing the adjuvant, whereby the resulting tablets are porous, strong, shape retaining and readily disintegratable. Volatilization can be effected by sublimation or application of 'vacuum. The adjuvant preferably comprises urethane, urea, ammonium carbonate, ammonium bicarbonate, hexamethylene-tetramine, benzoic acid, phthalic anhydride, naphthalene or camphor present in about 5 to 50 percent, especially about 10 to 30 percent, by weight of the total tablet mix.

13Claims, No Drawings PREPARATION OF POROUS TABLETS The present invention is concerned with a new process for the preparation of porous tablets.

Because of the ease of handling and the simplicity of dosing, not only pharmaceutical tablets but also reagent tablets are used to an ever increasing extent for diagnostic and analytical purposes. Most active materials and reagents cannot be tabletted by themselves since they form hard tablets which do not readily break down and, in addition, in many cases, tend to stick in the presses used.

Tablets which break down quickly are only obtained by the addition of disintegration agents, such as carboxymethyl-cellulose, starch or the like; filling materials, such as lactose, phosphates or the like; and lubricants, such as talc, stearic acid, paraffin or the like. Whereas it is simple to find suitable, physiologically compatible adjuvants for pharmaceuticals, reagent tablets which, generally speaking, are to give optically clear solutions, cannot be produced or can only be produced with difficulty in this manner. In particular, the lubricants which are generally used and which are intended to prevent the adherence of the tablet masses in the presses used are mostly insoluble in water. It has, therefore, been suggested to press together adhesive reagents with very large amounts of readily tablettable fillers or to use very high pressures for the pressing. However, both processes are unsatisfactory since the tablets formed are either unnecessarily large or are too hard and difficult to break down.

Another known process gives so-called molded tablets." In this case, the tablet components are formed into a paste with water or an organic solvent, in which at least one of the components partially dissolves, to give a stiff slurry which is formed in special machines to give tablets, whereafter the tablets are carefully dried. Upon evaporation of the solvent, the substances dissolved therein adhere the undissolved particles, whereby the tablets receive their strength; at the same time, small hollow spaces are formed into which solvents can again penetrate when the tablets are dropped into liquid. Although these tablets are satisfactory with respect to speed of dissolution they are frequently too soft and brittle due to the presence of very fine canals so that difficulties arise in packing and transport. Furthermore, the use of the process is limited due to the fact that many reagents, especially enzymes and indicators, are damaged by solvents, and organic solvent vapors necessitate special safety precautions during the production of the tablets.

It is, therefore, an object of the present invention to provide a process which permits the production of readily dissolved, porous tablets in conventional tablet presses, without having to add lubricants, explosive agents or solvents.

In accordance with the present invention the conventional process of mixing tablet components and pressing the mix into predetermined shape is modified by incorporating into the mix at least one inert readily volatilizable solid adjuvant, pressing the mix into shape, and thereafter volatilizing the adjuvant, whereby the resulting tablets are porous, strong, shape retaining and readily disintegratable.

Due to the hard pressing in conventional tabletting machines, there are formed tablets of great mechanical stability and, at the same time, the addition of sparingly soluble lubricants is unnecessary. Since the pressed tablets, in contradistinction to molded tablets, are

form-stable, they no longer shrink upon removal of the adjuvant. Therefore, when the adjuvant is removed, it

5 leaves behind comparatively large hollow spaces and canals, through which solvent can penetrate.

As adjuvants, there can be used, in principle, all readily sublimable materials or materials which can readily be converted into gaseous decomposition products and which are readily tablettable and do not react with the other components of the tablets. By way of example, there may be mentioned urethane, urea, ammonium carbonate and bicarbonate, hexamethylenetetramine, benzoic acid, phthalic anhydride, naphthalene and camphor, urethane being especially preferred.

The tablet masses for water-soluble reagent tablets and pharmaceutical tablets can, in addition to one or more active materials, contain conventional soluble carrier materials, for example sodium chloride, potassium chloride, borax, phosphates, oligosaccharides, polyethylene glycols, tensides and other appropriate inorganic and organic materials. The volatile solid adjuvants can account for about 5 50 percent and preferably about -30 percent of the total tablet mass. it being understood that in the case of a high proportion of adjuvant there are formed comparatively large hollow spaces and thus tablets which break down more quickly but are also more brittle than in the case of using a small proportion of adjuvant. Although the adjuvants can be completely removed, the production time for the new tablets according to the present invention is shortened when the adjuvants are allowed to remain behind in the tablets in trace amounts, for example of less than about 1% by weight.

Where the tablet components are of sufficient ther' mal stability, the adjuvants can be removed by simple heating of the tablets above the sublimation or decomposition point. In the case of sensitive tablet components, for example of enzymes, it is advantageous to work in a vacuum, the conventional freeze drying plants with condensation separator having proved to be especially advantageous for this purpose.

The following Examples are given for the purpose of illustrating the present invention:

EXAMPLE I Tablet A: 1.850 kg of potassium chloride are sieved and pressed to form tablets of 8 mm diameter containing 185 mg of potassium chloride.

Tablet Bl: 1.850 kg of potassium chloride are mixed with 350 g of urethane (ethyl-urethane), sieved and pressed to form tablets of 8 mm diameter containing 185 mg of potassium chloride and 35 mg of urethane.

The urethane is subsequently sublimed from these tablets over 5 hours in a freeze drying plant at 20C and at a pressure of IO to 10. mm Hg.

Tablet B2: 1.850 kg of potassium chloride are mixed with 350 g of ammonium bicarbonate, sieved and pressed to form tablets of 8 mm diameter containing 185 mg of potassium chloride and 35 mg of ammonium bicarbonate.

The ammonium bicarbonate is driven off from these tablets over 8 hours in a drying cabinet at 90C.

Tablet B3: 1.850 kg of potassium chloride are mixed with 350 g of urea, sieved and pressed to form tablets of 8 mm diameter containing 185 mg of potassium chloride and 35 mg of urea.

The urea is sublimed from these tablets over 16 hours in a vacuum cabinet at 110C and 15 mm Hg.

Tablet B4: 1.850 kg of potassium chloride are mixed with 350 g of urotropin, sieved and pressed to form tablets of 8 mm diameter containing 185 mg of potassium chloride and 35 mg of urotropin.

The urotropin is removed from these tablets over 16 hours in a vacuum cabinet at 90C and 15 mm Hg.

The results of tests carried out on these tablets are set out in the following Table 1:

TABLE 1 Tablet Height, Hardness. Dissolving Breakability,

mm kg Time, sec. see.

EXAMPLE 2 Tablet C: 1.5 kg of dextrose are granulated with 300 ml of 40 percent aqueous alcohol, dried and sieved. The granulate is dry mixed with 50 g of polyethylene glycol (M.W. 5000 6000) and pressed to form tablets of 8 mm diameter containing 150 mg of dextrose.

Tablet D1: 1.550 kg of dextrose-polyethylene glycol granulate are dry mixed with 300 g of urethane. The tablet mass is pressed to form tablets of 8 mm diameter containing 150 mg of dextrose and 30 mg of urethane.

The urethane is sublimed from these tablets over 8 hours in a drying cabinet at 40C.

Tablet D2: 1.550 kg of dextrose-polyethylene glycol granulate are dry mixed with 300 g of ammonium carbonate. The tablet mass is pressed to form tablets of 8 mm diameter containing 150 mg of dextrose and 30 mg of ammonium carbonate.

The ammonium carbonate is removed from these tablets over 8 hours in a drying cabinet at 75C.

Tablet D3: 1.550 kg of dextrose-polyethylene glycol granulate are dry mixed with 300 g of benzoic acid. The tablet mass is pressed to form tablets of 8 mm diameter containing 150 mg of dextrose and 30 mg of benzoic acid.

The benzoic acid is sublimed from these tablets over 16 hours in a vacuum cabinet at 90C and 15 mm Hg.

Tablet D4: 1.550 kg of dextrose-polyethylene glycol granulate are dry mixed with 300 g of camphor. The tablet mass is pressed to form tablets of 8 mm diameter containing 150 mg of dextrose and 30 mg of camphor.

TABLE 2 Tablet Height, Hardness,

Dissolving Time, sec.

Breakability, sec.

EXAMPLE 3 Tablet E: g of polyethylene glycol (M.W. 5000 6000) are dissolved in 80 ml of 40 percent aqueous ethanol. With this solution, there are mixed 388 g of glucose, which is then dried and sieved. The granulate obtained is dry mixed with 12.5 g of nicotinamide-adenine-dinucleotide (NAD), 3.75 g of 2,5-diphenyl-3-(4,5-dimethyl-thiazolyl-2)- tetrazolium bromide (MTT) and 0.75 g of N- methylphenazine-methylsulfate (PMS). The mixture is pressed to form tablets of 12 mm diameter, each tablet containing 12.5 mg of NAD, 3.75 mg of MTT and 0.75 mg of PMS.

Tablet F: 15 g of polyethylene glycol (M.W. 5000 6000) are dissolved in 80 ml of 40 percent aqueous alcohol. With this solution, there are mixed 388 g of glucose, which is then dried and sieved. The granulate obtained is dry mixed with 12.5 g of NAD, 3.75 g of MTT, 0.75 g of PMS and 80 g of urethane. The mixture is pressed to form reagent tablets of 12 mm diameter which contain, per tablet, 12.5 mg of NAD, 3.75 mg of MTT and 0.75 mg of PMS. The urethane is sublimed from these tablets over 8 hours in a freeze drying plant at 0C and 10 to lO 3 mm Hg.

The results of tests carried out on these tablets, in the manner described in Example 1, are set out in the following Table 3: 45

TABLE 3 Tablct Height,

Hardness, kg

Dissolving Time, sec.

Breakability,

sec.

EXAMPLE 4 Tablet G: 500 g of sodium chloride are ground,

mixed with 116 g of sodium p-nitrophenyl phosphate, precompressed and sieved. There are then pressed tablets of 5 mm diameter each containing 1 1.6 mg of sodium p-nitrophenyl phosphate.

Tablet H: 500 g of sodium chloride are ground,

mixed with 116 g of sodium p-nitrophenyl phosphate and 134 g of urethane, precompressed and sieved. There are then pressed tablets of 5 mm diameter containing 11.6 mg of sodium pnitrophenyl phosphate. These tablets are heated for 10 hours in a drying cabinet at 30C to sublime the urethane.

The results of tests carried out on these tablets, in the manner described in Example 1, are set out in the following Table 4:

The various components of the tablet mix including active materials, adjuvant, carrier, etc., may range in size from about 0,0l to 1,0 and preferably about 0.05 to 0,5 mm. Desirably the average size of the adjuvant particles ranges from about 5 to 50 percent and preferably about to 30 percent of that of the balance of the particles making up the tablet mix.

It will be appreciated that the instant specification and examples are set -forth by way of illustration and not limitation, and that various modifications and changes may be made without departing from the spirit and scope of the present invention.

What is claimed is:

1. In the production of pharmaceutical or reagent tablets which are to undergo disintegration in use wherein the tablet components are mixed and pressed into predetermined shape. the improvement which comprises incorporating into the mix at least one inert solid adjuvant, sublimable at a temperature up to about 1 10C pressing the mix into tablets, and thereafter subjecting the tablets to at least one of vacuum and heating to a temperature up to about 1 10C so as to sublime the adjuvant, whereby the resulting tablets are porous, strong, shape retaining and readily disintegratable.

2. Process according to claim 1, wherein the adjuvant is sublimed by application of a vacuum.

3. Process according to claim 1, wherein the adjuvant comprises about 5 to 50 percent by weight of the total tablet mix.

4. Process according to claim 3, wherein the adjuvant comprises about 10 to 30 percent by weight of the total tablet mix.

5. Process according to claim 1, wherein the tablet mix additionally comprises a soluble carrier.

6. Process according to claim 1, wherein the adjuvant is urethane.

7. Process according to claim 1, wherein the adjuvant is urea.

8. Process according to claim 1, wherein the adjuvant is hexamethylenetetramine.

9. Process according to claim 1, wherein the adjuvant is benzoic acid.

10. Process according to claim 1, wherein the adjuvant is phthalic anhydride.

11. Process according to claim 1, wherein the adjuvant is naphthalene.

12. Process according to claim 1, wherein the adjuvant is camphor.

13. The product produced by the process of claim 1.

1; 33 UNl'lEl) sm'uss l-A'LENI mutt CERTIFICATE OF CORRECTION Patent No. 3 ,885.,O26 4 Dated May 20 1975 Inventor (s) HELMUT HEINEMANN ET AL I It is certified that error appearsln the above-identified patent and that said Letters Patent are hereby corrected as shown below:

i 3 "1 Col. 2, line-58, cancel "l0 to l0 and substitute Col. 4, line 2, cancel "l0 to l0 and substitute Col. 4, line'hl, cancel 'l0 to l0 and substitute Signed and Sealed this thirtieth Day of September 1975 [SEAL] Arrest:

RUTH ct MASON c. MARSHALL DANN Allesling Officer Commissioner of Palnls and Trudtmarkx

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US1742515 *Oct 8, 1924Jan 7, 1930Ambrose J MandellMethod of making porous objects
US2887437 *Aug 22, 1956May 19, 1959Pfizer & Co CPalatable vitamin tablet containing an amino acid
US3175521 *Feb 23, 1961Mar 30, 1965Schering CorpApparatus for punching miniature tablets
US3371984 *Sep 6, 1963Mar 5, 1968Colgate Palmolive CoAir freshener
US3424842 *May 4, 1965Jan 28, 1969Merck Ag EManufacture of tablets directly from dry powders
US3632778 *Jun 10, 1970Jan 4, 1972Hoffmann La RocheTablets containing l-dopa
US3639286 *May 28, 1968Feb 1, 1972Triberti DomenicoSynthetic detergent in bar or cake form and the method to manufacture same
US3649545 *Jan 15, 1970Mar 14, 1972Lion Fat Oil Co LtdSynthetic detergent in masses and their manufacturing methods
US3653914 *Mar 20, 1970Apr 4, 1972Alberto Culver CoProduction of tablets
US3674700 *Apr 14, 1969Jul 4, 1972Gaiser Conrad JDetergent tablet of amorphous sodium silicate having inherent binding properties,containing a surfactant,and method of making such tablet
US3719599 *Nov 4, 1970Mar 6, 1973Lepetit SpaSolid lubricant composition and method of preparation
US3739048 *May 26, 1971Jun 12, 1973Sumitomo Electric IndustriesMethod of granulating powder
US3781428 *Jan 5, 1971Dec 25, 1973Ciba Geigy AgHydrophobic insecticidal compositions
US3789119 *Jun 1, 1971Jan 29, 1974Parke Davis & CoStabilized molded sublingual nitroglycerin tablets
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4062932 *Aug 5, 1976Dec 13, 1977University Of Southern CaliforniaProcess for the catalytic oxidation of hydrogen sulfide with sulfur dioxide
US4134943 *Dec 3, 1976Jan 16, 1979Boehringer Mannheim GmbhProduction of porous tablets
US4568547 *Feb 28, 1984Feb 4, 1986Herschler R JSolid pharmaceutical compositions comprising MSM and their production
US4883182 *Jan 12, 1988Nov 28, 1989Hughes Raymond JTamper evident capsule and insert device
US5516530 *Nov 4, 1992May 14, 1996Pfizer Inc.Porous shaped delivery devices and method of producing thereof
US5529789 *Nov 6, 1992Jun 25, 1996Pfizer, Inc.Method of producing porous delivery devices
US5853758 *Jul 10, 1996Dec 29, 1998Pfizer Inc.Preparation of tablets of increased strength
US6284270Aug 4, 1999Sep 4, 2001Drugtech CorporationMeans for creating a mass having structural integrity
US6294151Aug 12, 1997Sep 25, 2001Kyowa Hakko Kogyo, Co., Ltd.Isotopic urea tablets
US6376545Nov 10, 1999Apr 23, 2002Teva Pharmaceutical Industries, Ltd.Dispersible compositions containing L-DOPA ethyl ester
US6465010Jul 12, 2001Oct 15, 2002Drugtech CorporationMeans for creating a mass having structural integrity
US6509040Jun 22, 2001Jan 21, 2003R.P. Scherer CorporationFast dispersing dosage forms essentially free of mammalian gelatin
US6544552 *Jan 11, 2001Apr 8, 2003Particle And Coating Technologies, Inc.Method of producing porous tablets with improved dissolution properties
US6703424Feb 25, 2002Mar 9, 2004Teva Pharmaceutical Industries, Ltgd.Dispersible compositions containing L-DOPA ethyl ester
US6709669Apr 7, 2000Mar 23, 2004R. P. Scherer Technologies, Inc.Fast-dispersing dosage forms containing fish gelatin
US7214389Nov 22, 2001May 8, 2007Smithkline Beecham, PlcProcess
US7390503Aug 23, 2004Jun 24, 2008Barr Laboratories, Inc.Ondansetron orally disintegrating tablets
US7749533May 7, 2004Jul 6, 2010Akina, Inc.Highly plastic granules for making fast melting tablets
US8071128Jun 20, 2003Dec 6, 2011Kyowa Hakko Kirin Co., Ltd.Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8127516Dec 23, 2009Mar 6, 2012Hanmi Pharm. Co., Ltd.Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
US8313768Nov 20, 2012Mcneil-Ppc, Inc.Manufacture of tablet having immediate release region and sustained release region
US8343533Sep 22, 2010Jan 1, 2013Mcneil-Ppc, Inc.Manufacture of lozenge product with radiofrequency
US8357396Jan 22, 2013Kyowa Hakko Kirin Co., Ltd.Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8367111Feb 5, 2013Aptalis Pharmatech, Inc.Extended release dosage forms of propranolol hydrochloride
US8580313Dec 2, 2010Nov 12, 2013Aptalis Pharma LimitedFexofenadine microcapsules and compositions containing them
US8747895Sep 9, 2005Jun 10, 2014Aptalis Pharmatech, Inc.Orally disintegrating tablets of atomoxetine
US8784781Sep 22, 2010Jul 22, 2014Mcneil-Ppc, Inc.Manufacture of chewing gum product with radiofrequency
US8807979Sep 22, 2010Aug 19, 2014Mcneil-Ppc, Inc.Machine for the manufacture of dosage forms utilizing radiofrequency energy
US8858210Mar 21, 2011Oct 14, 2014Mcneil-Ppc, Inc.Manufacture of variable density dosage forms utilizing radiofrequency energy
US8865204Dec 18, 2012Oct 21, 2014Mcneil-Ppc, Inc.Manufacture of lozenge product with radiofrequency
US8871263Sep 22, 2010Oct 28, 2014Mcneil-Ppc, Inc.Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US8945618Mar 13, 2014Feb 3, 2015Kyowa Hakko Kirin Co., Ltd.Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8956650Jan 17, 2013Feb 17, 2015Kyowa Hakko Kirin Co., Ltd.Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8968769Sep 24, 2009Mar 3, 2015Mcneil-Ppc, Inc.Orally disintegrative dosage form
US9040086Aug 9, 2006May 26, 2015Aptalis Pharmatech, Inc.Timed, sustained release systems for propranolol
US9107807Aug 8, 2014Aug 18, 2015Mcneil-Ppc, Inc.Machine for the manufacture of dosage forms utilizing radiofrequency energy
US9161918May 2, 2005Oct 20, 2015Adare Pharmaceuticals, Inc.Timed, pulsatile release systems
US9161919Jul 19, 2011Oct 20, 2015Adare Pharmaceuticals, Inc.Timed, pulsatile release systems
US9192580Oct 14, 2003Nov 24, 2015R.P. Scherer Technologies, LlcFast-dispersing dosage forms containing fish gelatin
US9233105Oct 9, 2013Jan 12, 2016Adare Pharmaceuticals S.R.L.Fexofenadine microcapsules and compositions containing them
US9233491Mar 14, 2013Jan 12, 2016Johnson & Johnson Consumer Inc.Machine for production of solid dosage forms
US9358214Jun 2, 2003Jun 7, 2016Adare Pharmaceuticals, Inc.Timed, sustained release systems for propranolol
US20030021842 *Sep 18, 2002Jan 30, 2003Drugtech CorporationMeans for creating a mass having structural integrity
US20030022912 *Feb 7, 2002Jan 30, 2003Martino Alice C.Rapid-onset medicament for treatment of sexual dysfunction
US20030185886 *Mar 17, 2003Oct 2, 2003Hanmi Pharm. Co., Ltd.Process for the preparation of rapidly disintegrating tablet
US20030215500 *Jun 20, 2003Nov 20, 2003Motohiro OhtaIntrabuccally rapidly disintegrating tablet and a production method of the tablets
US20040023948 *Feb 26, 2003Feb 5, 2004Green Richard DavidFast-dispersing dosage form containing 5-HT1 agonists
US20040070102 *Nov 22, 2001Apr 15, 2004Valder Christoper EdmundNovel process
US20040071772 *Mar 5, 2002Apr 15, 2004Shoichi NaritaPreparations quickly disintegrating in oral cavity
US20040076666 *Oct 14, 2003Apr 22, 2004Richard GreenFast-dispersing dosage forms containing fish gelatin
US20040126427 *Dec 31, 2002Jul 1, 2004Venkatesh Gopi M.Extended release dosage forms of propranolol hydrochloride
US20040146556 *Oct 29, 2003Jul 29, 2004Noack Robert M.Oral extended release tablets and methods of making and using the same
US20050013857 *May 7, 2004Jan 20, 2005Yourong FuHighly plastic granules for making fast melting tablets
US20050043296 *Oct 2, 2003Feb 24, 2005Michael HawleyCompositions and methods for treating sexual dysfunction
US20060057199 *Sep 9, 2005Mar 16, 2006Venkatesh Gopi MOrally disintegrating tablets of atomoxetine
US20060078614 *Oct 12, 2005Apr 13, 2006Venkatesh Gopi MTaste-masked pharmaceutical compositions
US20060105038 *Aug 26, 2005May 18, 2006Eurand Pharmaceuticals LimitedTaste-masked pharmaceutical compositions prepared by coacervation
US20060105039 *Oct 21, 2005May 18, 2006Jin-Wang LaiTaste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060269607 *Aug 9, 2006Nov 30, 2006Eurand, Inc.Timed, sustained release systems for propranolol
US20070036852 *Aug 7, 2006Feb 15, 2007Dabhade Harsha MRapidly dispersing/disintegrating compositions
US20090060983 *Aug 30, 2007Mar 5, 2009Bunick Frank JMethod And Composition For Making An Orally Disintegrating Dosage Form
US20090068262 *Apr 3, 2008Mar 12, 2009Ilan ZalitRapid dissolution of combination products
US20090110716 *Oct 29, 2008Apr 30, 2009Frank BunickOrally disintegrative dosage form
US20090263480 *Oct 22, 2009Jin-Wang LaiTaste-masked pharmaceutical compositions prepared by coacervation
US20100016348 *Sep 24, 2009Jan 21, 2010Frank BunickOrally disintegrative dosage form
US20100016451 *Jan 21, 2010Frank BunickOrally Disintegrative Dosage Form
US20100021507 *Sep 30, 2009Jan 28, 2010Bunick Frank JMethod and Composition for Making an Orally Disintegrating Dosage Form
US20100105783 *Dec 23, 2009Apr 29, 2010Hanmi Pharm. Co., Ltd.Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
US20110070286 *Mar 24, 2011Andreas HugerthProcess for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US20110071183 *Mar 24, 2011Jen-Chi ChenManufacture of lozenge product with radiofrequency
US20110071184 *Mar 24, 2011Bunick Frank JManufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US20110071185 *Sep 22, 2010Mar 24, 2011Bunick Frank JManufacture of tablet in a die utilizing powder blend containing water-containing material
US20110212171 *Sep 1, 2011Eurand, Inc.Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP0914818A1 *Jun 12, 1997May 12, 1999Kyowa Hakko Kogyo Co., Ltd.Intraorally rapidly disintegrable tablet
EP1283703A1 *May 26, 2001Feb 19, 2003Hanmi Pharm. Co., Ltd.Rapidly disintegrating tablet and process for the manufacture thereof
EP1598061A1 *Jun 12, 1997Nov 23, 2005Kyowa Hakko Kogyo Co., Ltd.Intraorally rapidly disintegrable tablet
EP2457561A1 *Jul 5, 2010May 30, 2012Kyorin Pharmaceutical Co., Ltd.Tablet having hollow structure
EP2457561A4 *Jul 5, 2010Mar 5, 2014Kyorin Seiyaku KkTablet having hollow structure
WO2002055061A2 *Dec 10, 2001Jul 18, 2002Particle And Coating Technologies, Inc.Method of producing porous tablets with improved dissolution properties
WO2002055061A3 *Dec 10, 2001Sep 25, 2003Particle And Coating TechnologMethod of producing porous tablets with improved dissolution properties
Classifications
U.S. Classification424/465, 516/DIG.100, 106/122, 264/122, 264/49, 264/109, 264/101
International ClassificationA61K9/20
Cooperative ClassificationY10S516/01, A61K9/2095
European ClassificationA61K9/20P